Anteris reaches 100 patients treated with DurAVR THV; strong one-year safety and efficacy data

Anteris Technologies Global Corp.

Over 100 patients treated with DurAVR THV, including de novo, valve-in-valve, and bicuspid cases.
65 patients completed 30-day primary endpoints; safety and efficacy demonstrated.
One-year data on 37 patients shows sustained large effective orifice areas and low mean pressure gradients.
No valve or cardiovascular mortality at one year; excellent safety profile.
Pivotal trial on track to commence Q3 2025, pending FDA approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.